Drugs for Gastrointestinal Stromal Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 189)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Erlotinib |
Approved, Investigational |
Phase 4 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
2 |
|
Esomeprazole |
Approved, Investigational, Vet_approved |
Phase 4 |
|
73590-58-6, 119141-88-7 |
9568614 4594 |
Synonyms:
( -)-Omeprazole
(−)-omeprazole
(-)-Omeprazole
(S)-(−)-omeprazole
(S)-(-)-Omeprazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
(S)-Omeprazole
(S)-omeprazole|Nexium®
2,3,5-Trimethylpyridine/Omeprazole
A02BC05
Alenia
Antra
Antra mups
AstraZeneca brand OF esomeprazole magnesium
Audazol
Aulcer
Axagon
Belmazol
Ceprandal
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
EMOZUL
Epirazole
Erbolin
Escz
Esofag
Esomeprazol
Esomeprazole
Ésoméprazole
Esomeprazole magnesium
Esomeprazole potassium
Esomeprazole sodium
Esomeprazole strontium
Esomeprazole strontium anhydrous
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168/68|Losec®|Prilosec®
H-168/68
Indurgan
Inexium paranova
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
LOSEC MUPS
Lucen
Magnesium, omeprazole
Mepral
MEZZOPRAM
Miol
Miracid
Mopral
Morecon
Nexiam
Nexium
NEXIUM CONTROL
NEXIUM I.V.
Nexium IV
Nilsec
Nopramin
|
Nuclosina
Ocid
Olexin
Omapren
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole
Omeprazole magnesium
Omeprazole pellets
Omeprazole S-form
Omeprazole sodium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprol
OMERAN
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
OMP
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick_808
Prilosec
Prilosec otc
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
Sanamidol
Secrepina
Sodium, omeprazole
Strontium, esomeprazole
Tedec ulceral
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
VENTRA
Victrix
ZANPROL
Zefxon
Zegerid
Zepral
Zimor
Zoltum
|
|
3 |
|
Midazolam |
Approved, Illicit |
Phase 4 |
|
59467-70-8 |
4192 |
Synonyms:
Buccolam
Buccolam®|Dormicum®|Nayzilam®|USL261 (nasal spray formulation)|Versed®
Dea no. 2884
Dormicum
Hydrochloride, midazolam
Maleate, midazolam
Mezolam
Midazolam
Midazolam base
MIDAZOLAM CIV
|
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Nayzilam
USL261
USL-261
Versed
|
|
4 |
|
Caffeine |
Approved |
Phase 4 |
|
58-08-2 |
2519 |
Synonyms:
1,3,7-TRIMETHYL-2,3,6,7-TETRAHYDRO-1H-PURINE-2,6-DIONE
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-TRIMETHYLPURINE-2,6-QUINONE
1,3,7-Trimethylxanthine
137X
1-Methyltheobromine
1-Methyl-theobromine
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
7-Methyl theophylline
7-Methyltheophylline
Alert-Pep
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anoquan
Berlin-chemie brand OF caffeine
Bristol-myers squibb brand OF caffeine
Cafamil
CAFCIT
Cafecon
Cafeina
Cafeína
Cafeine
Caféine
Cafergot
Caffedrine
Caffedrine Caplets
Caffein
Caffeine
CAFFEINE MELTING POINT STANDARD
Caffeine Pure
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeinum
Caffine
Cafipel
CFF
Coffein
COFFEINE
Coffeinum
Coffeinum N
Coffeinum purrum
Compound 65
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
Durvitan
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA NO. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline brand OF caffeine
Guaranine
Hycomine
Invagesic
|
Invagesic Forte
Keep Alert
Kofein
Koffein
Lanorinal
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura brand OF caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Migergot
Miudol
Monohydrate caffeine
Monomethyl Derivative of Theophylline
Natural Caffeinum
Nix Nap
No doz
Nodaca
No-Doz
NODOZ
NODOZ CAPLETS AND CHEWABLE TABLETS
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
NSC-5036
Organex
Orphengesic
Orphengesic Forte
Passauer brand OF caffeine
Pep-Back
Percoffedrinol N
Percutaféine
Peyona®
Phensal
Pierre fabre brand OF caffeine
PRO-PLUS
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick pep
Quick-pep
QuickPep
Refresh'n
Republic drug brand OF caffeine
Respia
Seid brand OF caffeine
SK 65 Compound
Stim
Synalgos-Dc
Teina
Teína
Thein
Theine
Theobromine ME
Theophylline ME
Thompson brand 1 OF caffeine
Thompson brand 2 OF caffeine
Triad
Ultra Pep-Back
Vivarin
Wake-Up
Wigraine
YEAST-VITE
ZANTHINE
|
|
5 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
6 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
7 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
8 |
|
Anesthetics |
|
Phase 4 |
|
|
|
9 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
10 |
|
Antacids |
|
Phase 4 |
|
|
|
11 |
|
Proton Pump Inhibitors |
|
Phase 4 |
|
|
|
12 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
13 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
14 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
15 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
16 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
17 |
|
GABA Modulators |
|
Phase 4 |
|
|
|
18 |
|
Central Nervous System Stimulants |
|
Phase 4 |
|
|
|
19 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Imatinib Mesylate |
|
Phase 4 |
|
220127-57-1 |
|
Synonyms:
GLEEVEC
GLIVEC
IMATINIB MESILATE
IMATINIB MESYLATE
|
IMATINIB METHANESULFONATE
STI571
STI-571
|
|
21 |
|
Formaldehyde |
Approved, Vet_approved |
Phase 3 |
|
50-00-0 |
712 |
Synonyms:
Aldeide formica
Fannoform
Formaldehído
Formaldehyd
Formaldehyde
Formaldehyde solution
FORMALIN
Formalina
Formaline
Formalith
Formic aldehyde
|
Formol
Hyperband
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
|
|
22 |
|
Orange |
Approved |
Phase 2, Phase 3 |
|
|
|
23 |
|
Bevacizumab |
Approved, Investigational |
Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
24 |
|
Dasatinib |
Approved, Investigational |
Phase 3 |
|
302962-49-8 |
3062316 |
Synonyms:
(18F)-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Anh. dasatinib
Anhydrous dasatinib
BMS 345825
BMS 345825|BMS 354825|BMS 35482513|Sprycel®
BMS 354825
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
|
DASATINIB
Dasatinib (anh.)
dasatinib (anhydrous)
DASATINIB ANHYDROUS
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
|
|
25 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 3 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
26 |
|
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium |
Experimental |
Phase 3 |
|
461-06-3 |
|
Synonyms:
CARNITINE
CARNITINE CHLORIDE
|
|
|
27 |
|
Crenolanib |
Investigational |
Phase 3 |
|
670220-88-9 |
10366136 |
Synonyms:
ARO 002
ARO-002
ARO-002|CP 868596|CP-868,596|CP-868596
CP 868596
|
CP-868,596
CP-868596
CP-868596CRENOLANIB
Crenolanib
|
|
28 |
|
Hormones |
|
Phase 3 |
|
|
|
29 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
30 |
|
Analgesics |
|
Phase 3 |
|
|
|
31 |
|
Protein Kinase Inhibitors |
|
Phase 3 |
|
|
|
32 |
|
Tin Fluorides |
|
Phase 3 |
|
|
|
33 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
34 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
35 |
|
Antibodies |
|
Phase 3 |
|
|
|
36 |
|
Antineoplastic Agents, Immunological |
|
Phase 3 |
|
|
|
37 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
38 |
|
Immunoglobulins, Intravenous |
|
Phase 3 |
|
|
|
39 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
40 |
|
Endothelial Growth Factors |
|
Phase 3 |
|
|
|
41 |
|
Calcium |
Nutraceutical |
Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
42 |
|
Apixaban |
Approved |
Phase 2 |
|
503612-47-3 |
10182969 |
Synonyms:
APIXABAN
APIXABÁN
Apixabanum
BMS 562247-01
|
BMS-562247
BMS-562247|Eliquis®
BMS-562247-01
Eliquis
|
|
43 |
|
Rivaroxaban |
Approved |
Phase 2 |
|
366789-02-8 |
9875401 |
Synonyms:
BAY 59-7939
BAY 59-7939|Xarelto®
BAY59-7939
BAY-59-7939
|
JNJ39039039
JNJ-39039039
RIVAROXABAN
XARELTO
|
|
44 |
|
Heparin, bovine |
Approved, Investigational, Withdrawn |
Phase 2 |
|
9005-49-6 |
22833565 9812414 772 |
Synonyms:
Adomiparin
alpha-Heparin
Ariven
Arteven
Bemiparin
BOVINE HEPARIN
Calcilean
CALCIPARINE
Certoparin
CLEXANE
Clexane®|enoxaparin sodium|Lovenox®|PK-10169|RP-54563
Clivarin
Clivarine
DALTEPARIININATRIUM
Dalteparin
DALTEPARIN SODIUM
dalteparin sodium|Fragmin®
DALTEPARIN SODNÁ SŮL
DALTEPARIN SODYUM
DALTEPARINA SODICA
DALTEPARINA SÓDICA
DALTEPARINE SODIQUE
DALTÉPARINE SODIQUE
DALTEPARINNATRIUM
DALTEPARIN-NATRIUM
DALTEPARIN-NÁTRIUM
DALTEPARINO NATRIO DRUSKA
DALTEPARINUM NATRICUM
DALTEPARYNA SODOWA
Depo-Heparin
ENOXAPARIN
ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE)
ENOXAPARIN SODIUM SALT
Eparina
Eparina [DCIT]
Fluxum
FR-860
FRAGMIN
Fragmin A
Fragmin B
Fraxiparin
Hed-Heparin
Hepalean
HEPARIN
Heparin Cy 216
|
HEPARIN FRAGMENT KABI 2165
Heparin Leo
Heparin Lock Flush
HEPARIN SODIUM
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparina
HEPARINATE
Heparine
HEPARINIC ACID
Heparinsodiumsalt
Heparinum
Hepathrom
HepFlush®
HEP-LOCK
KABI-2165
Leparan
Lipo-Hepin
LIQUAEMIN
Liquaemin Sodium
Liquemin
LOVENOX
LOVENOX (PRESERVATIVE FREE)
LOW LIQUEMINE
Low molecular weight heparin sodium
Multiparin
Novoheparin
Pabyrin
PANHEPRIN
Parnaparin
Parnaparin sodium
Parvoparin
PK-10169
Pularin
Reviparin
RP-54563
Sandoparin
SODIUM HEPARIN
Sublingula
TEDELPARIN
Thromboliquine
Unfractionated heparin
Vetren
Vitrum AB
|
|
45 |
|
Reviparin |
Approved, Investigational |
Phase 2 |
|
9041-08-1 |
|
Synonyms:
INNOHEP
Innohep®|tinzaparin sodium
LNH1
LNH-1
LOGIPARIN
|
Reviparin sodium
TINZAPARIN
Tinzaparin sodium
Tinzaparina
|
|
46 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
47 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
48 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
49 |
|
Capecitabine |
Approved, Investigational |
Phase 2 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
50 |
|
Infigratinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
872511-34-7 |
53235510 |
Synonyms:
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea
BGJ 398|BGJ-398|BGJ398|NVP-BGJ398|Truseltiq®
BGJ398
|
BGJ-398
INFIGRATINIB
MVP-BGJ398
NVP-BGJ398
|
|
Interventional clinical trials:
(show top 50)
(show all 335)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors |
Unknown status |
NCT00777504 |
Phase 4 |
usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor |
2 |
Multicenter, Single-arm, Two Stage Phase II Trial of RAD001 (Everolimus) With Imatinib in Imatinib-resistant Patients With Progressive GIST |
Completed |
NCT00510354 |
Phase 4 |
Imatinib mesylate |
3 |
A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate |
Completed |
NCT00793871 |
Phase 4 |
Sunitinib Malate (SU011248) |
4 |
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) |
Completed |
NCT00171977 |
Phase 4 |
Imatinib Mesylate |
5 |
The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) or Gastrointestinal Stromal Tumour (GIST) |
Completed |
NCT02800330 |
Phase 4 |
Esomeprazole 40mg concomitantly;Esomeprazole 40mg before;Regorafenib 160mg or 120mg |
6 |
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients |
Completed |
NCT01402089 |
Phase 4 |
Sunitinib;Erlotinib;Midazolam;Caffeine |
7 |
An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment |
Active, not recruiting |
NCT00756509 |
Phase 4 |
Nilotinib |
8 |
Extension Protocol for Patients Previously Treated in Avapritinib Clinical Trials |
Active, not recruiting |
NCT04825574 |
Phase 4 |
Avapritinib |
9 |
An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment |
Active, not recruiting |
NCT01735955 |
Phase 4 |
Nilotinib |
10 |
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment |
Active, not recruiting |
NCT01742299 |
Phase 4 |
imatinib mesylate |
11 |
Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib. |
Terminated |
NCT00461929 |
Phase 4 |
|
12 |
Phase III Randomized, Intergroup, International Trial Assessing the Clinical Activity of STI-571 at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the KIT Receptor Tyrosine Kinase (CD117) |
Unknown status |
NCT00685828 |
Phase 3 |
imatinib mesylate |
13 |
Efficacy of Adjuvant Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index. Multicenter, Prospective, Randomized Study. Etude Multicentrique, Prospective, randomisée |
Unknown status |
NCT02576080 |
Phase 3 |
Imatinib |
14 |
Endoscopic Ultrasonography Guided Fine Needle Biopsy (EUS-FNB) vs. Single-incision Needle-knife (SINK) Biopsy for Diagnosis of Upper Gastrointestinal Subepithelial Lesions |
Unknown status |
NCT02866045 |
Phase 3 |
|
15 |
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) |
Completed |
NCT00785785 |
Phase 3 |
Nilotinib (AMN107);imatinib (STI571) |
16 |
A Randomized, Open Label, Two-Treatment, Multiple Dose, Steady State, Two-period, Cross-over, Multi-Centre Comparative Bioequivalence Study of Imatinib Mesylate Tablet 400 mg of Amneal Pharmaceuticals, USA With GLEEVEC® (Imatinib Mesylate) Tablets 400 mg Distributed by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions |
Completed |
NCT02103322 |
Phase 2, Phase 3 |
Imatinib Mesylate Tablets, 400 mg |
17 |
Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib Mesylate (Glivec) Versus No Further Therapy After Complete Surgery |
Completed |
NCT00103168 |
Phase 3 |
imatinib mesylate |
18 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor |
Completed |
NCT00075218 |
Phase 3 |
Placebo;SU011248 |
19 |
A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec™) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST) |
Completed |
NCT00041197 |
Phase 3 |
imatinib mesylate |
20 |
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib to Sunitinib in Patients With Gastrointestinal Stromal Tumor After Progression With Imatinib at 400mg as First Line Treatment |
Completed |
NCT01694277 |
Phase 3 |
Masitinib;Sunitinib |
21 |
Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy |
Completed |
NCT01265810 |
Phase 3 |
|
22 |
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) |
Completed |
NCT03465722 |
Phase 3 |
avapritinib;regorafenib |
23 |
A Prospective, Double Blind, Randomized, Placebo-Controlled Phase III Trial of Imatinib Re-Challenge in Patients With Gastrointestinal Stromal Tumor Who Had Benefit From Prior Imatinib But Progression From Both Imatinib and Sunitinib |
Completed |
NCT01151852 |
Phase 3 |
Imatinib;Placebo |
24 |
A Randomized, Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib Versus Best Supportive Care With or Without a Tyrosine Kinase Inhibitor (Investigator's Choice) in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Both Imatinib and Sunitinib |
Completed |
NCT00471328 |
Phase 3 |
Nilotinib |
25 |
A Prospective Multicentric Randomized Study of Glivec® in Patients With Advanced Gastrointestinal Stromal Tumors Expressing C-kit Comparing Treatment Interruption After 5 Years vs Treatment Maintenance |
Completed |
NCT00367861 |
Phase 3 |
interruption of Glivec® |
26 |
A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies |
Completed |
NCT03353753 |
Phase 3 |
DCC-2618;Placebo Oral Tablet |
27 |
Short (12 Months) Versus Long (36 Months) Duration of Adjuvant Treatment With the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST With a High Risk of Recurrence |
Completed |
NCT00116935 |
Phase 3 |
imatinib mesylate;imatinib |
28 |
Phase III Study of L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Patients With Gastrointestinal Stromal Tumors (GISTs) (Single-center Study) |
Completed |
NCT03426722 |
Phase 3 |
L-carnitine;Placebo |
29 |
An Open-label Trial of Glivec in Patients With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Expressing C-kit. |
Completed |
NCT00293124 |
Phase 3 |
Glivec |
30 |
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib |
Completed |
NCT01271712 |
Phase 3 |
Regorafenib (Stivarga, BAY73-4506);Placebo;Best supportive care |
31 |
Prospective, Explorative Trial for the Detection of Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)Harboring Activating Mutations of CKIT or PDGFRA Pre/Post Surgery or Pre/Under Treatment With a Tyrosine Kinase Inhibitor or Progressive Disease Irrespective of Current or Planned Treatment. An Open-label, Non-randomized, Multicenter Phase IIIb Clinical Trial |
Completed |
NCT01462994 |
Phase 3 |
|
32 |
An Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. |
Completed |
NCT01289028 |
Phase 3 |
Nilotinib |
33 |
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) |
Recruiting |
NCT02260505 |
Phase 3 |
Imatinib maintenance |
34 |
A Phase III, Open Label, Randomised,Controlled, Multi-centre Study to Assess the Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib |
Recruiting |
NCT04409223 |
Phase 3 |
Famitinib capsules;Sunitinib Capsules |
35 |
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors |
Recruiting |
NCT05208047 |
Phase 3 |
CGT9486 plus sunitinib;CGT9486;Sunitinib |
36 |
Near-infrared Fluorescence Imaging With IndoCyanine Green for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours: a Pilot Study |
Recruiting |
NCT04761172 |
Phase 2, Phase 3 |
|
37 |
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study |
Recruiting |
NCT02413736 |
Phase 3 |
Imatinib |
38 |
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib |
Active, not recruiting |
NCT03673501 |
Phase 3 |
DCC-2618;Sunitinib |
39 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Crenolanib in Subjects With Advanced or Metastatic Gastrointestinal Stromal Tumors With a D842V Mutation in the PDGFRA Gene |
Active, not recruiting |
NCT02847429 |
Phase 3 |
Crenolanib;Placebo |
40 |
A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 Mg Daily Of Imatinib |
Terminated |
NCT00372567 |
Phase 3 |
sunitinib malate;imatinib mesylate |
41 |
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors |
Terminated |
NCT00324987 |
Phase 3 |
Imatinib Mesylate |
42 |
Phase III Randomized, Intergroup Trial Assessing the Clinical Activity Of STI-571 at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the Kit Receptor Tyrosine Kinase (CD117) |
Terminated |
NCT00009906 |
Phase 3 |
Imatinib Mesylate |
43 |
A Phase III Randomized Study Evaluating Surgery of Residual Disease in Patients With Metastatic Gastro-intestinal Stromal Tumor Responding to Imatinib Mesylate. |
Terminated |
NCT00956072 |
Phase 3 |
imatinib mesylate |
44 |
A Prospective, Multicenter, Randomised, Double-blinded, Placebo-controlled, Two-parallel Groups, Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary Gastrointestinal Stromal Tumor (GIST) After Complete Surgery and With High Risk of Recurrence |
Terminated |
NCT02009423 |
Phase 3 |
Masitinib;Placebo |
45 |
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients With Metastatic and/or Unresectable GIST Following Failure of at Least Imatinib and Sunitinib |
Terminated |
NCT00688766 |
Phase 3 |
retaspimycin hydrochloride (IPI-504);placebo |
46 |
Randomized Phase III Trial Comparing Nilotinib 800mg to Imatinib 800 mg for the Treatment of Patients With Advanced and/or Metastatic Gastrointestinal Stromal Tumors Refractory to Imatinib 400 mg |
Terminated |
NCT00751036 |
Phase 3 |
Nilotinib;Imatinib |
47 |
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumor in First Line Medical Treatment |
Terminated |
NCT00812240 |
Phase 3 |
Masitinib;Imatinib |
48 |
A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib In Metastatic GIST Patients With Imatinib Trough Levels Less Than 1100 Nanograms/mL |
Terminated |
NCT01031628 |
Phase 3 |
Imatinib mesylate |
49 |
A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor |
Unknown status |
NCT02336724 |
Phase 2 |
Famitinib |
50 |
Use of a Quick Skin Sealant in Prevention of Surgical Site Infection After Laparoscopic Tumor Resection |
Unknown status |
NCT02426762 |
Phase 2 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
regorafenib
sunitinib
|
sunitinib malate
|
|